$AVTX News

Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3

Guggenheim Downgrades Avalo Therapeutics to Neutral

This Avalo Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $22

HC Wainwright & Co. Downgrades Avalo Therapeutics to Neutral

BTIG Maintains Buy on Avalo Therapeutics, Lowers Price Target to $10

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress

Avalo Therapeutics To Present Abdakibart Data At EADV Congress 2026

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Do Avalo Therapeutics’ (AVTX) Widening Losses But Better EPS Reveal a Turning Point in Strategy?

Guggenheim Maintains Buy on Avalo Therapeutics, Lowers Price Target to $48

HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Lowers Price Target to $30

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Avalo Therapeutics Q2 EPS $(0.83) Misses $(0.58) Estimate

Avalo Therapeutics Files Prospectus For Offering Up To 128,189 Common Shares On Behalf Of Selling Shareholders

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum